T-cell responses in hepatitis B and C virus infection: Similarities and differences

Emerging Microbes and Infections

Volumn 2, Issue , 2013, Pages

  Schmidt, Julia ^a   Blum, Hubert E ^a   Thimme, Robert ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adaptive immunity; CD4+ and CD8+ T cells; Hepatitis B virus; Hepatitis C virus

Indexed keywords

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER DISEASE; LYMPHOCYTE FUNCTION; MIXED INFECTION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRAL CLEARANCE;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84879373530     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2013.14     Document Type: Review

References (128)

1. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012; 61: 1226-1234.
2. Bauer T, Sprinzl M, Protzer U. Immune control of hepatitis B virus. Dig Dis 2011; 29: 423-433.
3. Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and future challenges. QJM 2012; 105: 109-113.
4. Aman W, Mousa S, Shiha G, Mousa SA. Current status and future directions in the management of chronic hepatitis C. Virol J 2012; 9: 57.
5. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21: 379-384.
6. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973.
7. Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 2007; 13: 14-21.
8. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
9. Yan H, Zhong G, Xu G et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049.
10. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010; 52: 282-284.
11. Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011; 5: 644-653.
12. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592.
13. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108.
14. +. Science 1998; 282: 938-941.
15. Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805.
16. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 2009; 83: 2011-2014.
17. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71-99.
18. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.
19. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond) 2011; 61: 531-540.
20. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol 2003; 39 Suppl 1: S26-S30.
21. Tujios SR, Lee WM. New advances in chronic hepatitis B. Curr Opin Gastroenterol 2012; 28: 193-197.
22. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Rev Med Virol 2003; 13: 57-68.
23. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010; 58: 258-266.
24. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436: 946-952.
25. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-1512.
26. Thimme R, Oldach D, Chang KM et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406.
27. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655.
28. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662.
29. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virusencoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442-3449.
30. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047-1058.
31. + T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 3447-3458.
32. + T helper cells in chronic HCV infection. Hepatology 2005; 41: 1019-1028.
33. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000; 191: 1269-1280.
34. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601.
35. Webster GJ, Reignat S, Maini MK et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117-1124.
36. Penna A, Del Prete G, Cavalli A et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25: 1022-1027.
37. Asabe S, Wieland SF, Chattopadhyay PK et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83: 9652-9662.
38. + T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012; 209: 61-75.
39. Day CL, Seth NP, Lucas M et al. Exvivoanalysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003; 112: 831-842.
40. Ulsenheimer A, Gerlach JT, Gruener NH et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003; 37: 1189-1198.
41. Urbani S, Amadei B, Fisicaro P et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006; 44: 126-139.
42. Cooper S, Erickson AL, Adams EJ et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449.
43. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99: 15661-15668.
44. + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
45. + T cell response in mediating HCV clearance and evolution. Hepatology 2006; 43: 563-572.
46. *57 and preservation of targeted epitopes. Gastroenterology 2011; 140: 686-696.
47. McKiernan SM, Hagan R, Curry M et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004; 40: 108-114.
48. + T cell response against HIV-1. PLoS Med 2006; 3: e403.
49. *03 allele in hepatitis C virus infection. Gut 2011; 60: 1563-1571.
50. + T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2010; 184: 287-295.
51. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829.
52. Mason WS, Litwin S, Xu C, Jilbert AR. Hepatocyte turnover in transient and chronic hepadnavirus infections. J Viral Hepat 2007; 14 Suppl 1: 22-28.
53. Kennedy PT, Sandalova E, Jo J et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012; 143: 637-645.
54. + T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 2009; 136: 1391-1401.
55. Ando K, Hiroishi K, Kaneko T et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158: 5283-5291.
56. Gremion C, Grabscheid B, Wölk B et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004; 78: 2152-2157.
57. Micco L, Peppa D, Loggi E et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013; 58: 225-233.
58. + memory T cells. J Virol 2008; 82: 10017-10031.
59. Boni C, Laccabue D, Lampertico P et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963-973.
60. Peppa D, Micco L, Javaid A et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 2010; 6: e1001227.
61. + T cell failure in hepatitis C virus infection. World J Gastroenterol 2007; 13: 4839-4847.
62. Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 2010; 52: 616-619.
63. + T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181, 1528-1536.
64. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-499.
65. + T-cell failure during chronic hepatitis C virus infection. Hepatology 2005; 42: 828-837.
66. Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225.
67. + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719.
68. + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6: e1000947.
69. + T-cell responses during chronic viral infection. J Virol 2006; 80: 8627-8638.
70. Lopes AR, Kellam P, Das A et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest 2008; 118: 1835-1845.
71. + cells targeting the virus in chronic hepatitis C virus infection. Cell Immunol 2011; 269: 104-114.
72. Fisicaro P, Valdatta C, Massari M et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010; 138: 682-693.
73. Penna A, Pilli M, Zerbini A et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007; 45: 588-601.
74. Radziewicz H, Ibegbu CC, Fernandez ML et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545-2553.
75. Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229, 114-125.
76. + T cells associated with reversible immune dysfunction. J Virol 2007; 81: 9249-9258.
77. Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 2009; 50: 1625-1637.
78. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
79. + T lymphocytes in the liver. J Immunol 2007; 178: 2714-2720.
80. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
81. + T-cell function. Hepatology 2010; 52: 1934-1947.
82. Schurich A, Khanna P, Lopes AR et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011; 53: 1494-1503.
83. Nakamoto N, Cho H, Shaked A et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009; 5: e1000313.
84. Fisicaro P, Valdatta C, Massari M et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 2012; 143: 1576-1585.e4.
85. Nebbia G, Peppa D, Schurich A et al. Upregulation of the tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012; 7: e47648.
86. + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 120: 4546-4557.
87. + T cells. J Virol 2009; 83: 9122-9130.
88. You Q, Cheng L, Kedl RM, Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 2008; 48: 978-990.
89. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol 2007; 15: 143-146.
90. Flynn JK, Dore GJ, Hellard M et al. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat 2010; 18: 549-561.
91. Dunn C, Peppa D, Khanna P et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137: 1289-1300.
92. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; 12: 1301-1309.
93. Ejrnaes M, Filippi CM, Martinic MM et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006; 203: 2461-2472.
94. Shin HD, Winkler C, Stephens JC et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97: 14467-14472.
95. Abel M, Sène D, Pol S et al. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 2006; 44: 1607-1616.
96. Miyazoe S, Hamasaki K, Nakata K et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002; 97: 2086-2092.
97. Knapp S, Hennig BJ, Frodsham AJ et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55: 362-369.
98. Persico M, Capasso M, Persico E et al. Interleukin-10-1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol 2006; 45: 779-785.
99. + cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol 2007; 81: 5882-5892.
100. Billerbeck, E. Bottler, T, Thimme, R. Regulatory T cells in viral hepatitis. World J Gastroenterol 2007; 13: 4858-4864.
101. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007; 7: 804-813.
102. Miroux C, Vausselin T, Delhem N. Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response. Expert Opin Biol Ther 2010; 10: 1563-1572.
103. Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778.
104. + regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 2007; 19: 133-140.
105. + regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322-3328.
106. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol 2008; 82: 21-30.
107. Stoop JN, Claassen MA, Woltman AM et al. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. Clin Immunol 2008; 129: 419-427.
108. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003; 38: 1437-1448.
109. + regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062-1071.
110. + T cells during chronic hepatitis C virus infection. J Virol 2005; 79: 7860-7867.
111. + T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 2007; 47: 316-324.
112. + T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol 2006; 144: 188-196.
113. Whalley SA, Brown D, Webster GJ et al. Evolution of hepatitis B virus during primary infection in humans: transient generation of cytotoxic T-cell mutants. Gastroenterology 2004; 127: 1131-1138.
114. Rehermann B, Pasquinelli C, Mosier SM, Chisari FV. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995; 96: 1527-1534.
115. Whalley SA, Brown D, Webster GJ et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369: 407-410.
116. Desmond CP, Gaudieri S, James IR et al. Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol 2012; 86: 1181-1192.
117. Chang KM, Rehermann B, McHutchison JG et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997; 100: 2376-2385.
118. Erickson AL, Kimura Y, Igarashi S et al. The outcome of hepatitis C virus infection is predicted by escape mutaions in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 885-895.
119. + T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714.
120. Cox AL, Mosbruger T, Mao Q et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005; 201: 1741-1752.
121. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42: 104-112.
122. + T lymphocytes. J Viral Hepat 2006; 13: 121-130.
123. + T-cell failure in chronic hepatitis C virus infection. Hepatology 2008; 47: 1824-1836.
124. Timm J, Lauer GM, Kavanagh DG et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004; 200: 1593-604.
125. Tester I, Smyk-Pearson S, Wang P et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 2005; 201: 1725-1731.
126. + T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009; 119: 376-386.
127. + T-cell responses during chronic hepatitis C virus infection. J Gen Virol 2010; 91: 1396-1406.
128. Fuller MJ, Shoukry NH, Gushima T et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010; 51: 378-387.